 |
||||
 |
|
|
|
|
 |
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
 |
||||
 |
 |
||
|
The Molecular and Experimental Pathology Core of the DDRCC provides services vital to the study of intestinal disease, particularly immune-mediated, infectious, neoplastic and inflammatory bowel diseases, in human and animal tissues. In simplest terms, the core components can be broken into four major areas: (1) human and animal (primarily mouse) tissue banking, (2) anatomic pathology review and consultation and tissue analysis (including immunohistochemistry, laser capture microdissection, tissue arrays), and (3) guidance in the use and design of animal models of intestinal disease and (4) flow cytometry. The Molecular and Experimental Pathology Core was created through a reorganization of the Molecular Medicine Core in 2003 in an effort to better meet the needs of the DDRCC. A survey of DDRCC membership performed at that time determined that the services most needed focused on access to human and animal tissues, access to advanced tools, training in their use, expertise in data interpretation, and assistance in the use of animal models. The unification of these services within the Molecular and Experimental Pathology Core has provided centralized management with resulting increases in efficiency as well as improved coordination of services. The Administrative Director of the Molecular and Experimental Pathology Core, Dr. Jerrold Turner M.D., Ph.D., oversees the operations of all components and is directly involved in all human tissue-related operations, provides anatomic pathology review and consultation services, and supervises human and animal tissue immunostaining and tissue array production. The Co-Director of the Molecular and Experimental Pathology Core, Dr. Yang-Xin Fu, M.D., Ph.D., directs the mouse tissue bank, advises on mouse tissue use, including mouse tissue immunostaining services and animal models services, provides direct consultation for animal model use and development, particularly of IBD-related models, and oversees the operation of flow cytometry services. Drs. Turner and Fu are responsible for ensuring proper scientific direction and efficient use of services and facilities of their respective sections. Preference for
services and facilities are given to a) NIDDK funded investigators,
b) recipients of current pilot and feasibility funds, c) non-funded
junior investigators in digestive diseases, and d) established investigators
outside of the area of digestive diseases who are interested extending
into this area. This core offers training and consultation as part
of its services. Users are encouraged to take advantage of this
if they foresee extended or heavy use of facilities. Users are asked
to acknowledge the DDRCC in all publications resulting from use
of core service and facilities.
| ||
Director: 
Co-Director: